
Benzinga Pro data, Angion Biomedica (NASDAQ:ANGN) reported Q1 sales of $1.65 million. Earnings fell to a loss of $14.24 million, resulting in a 195.63% decrease from last quarter. In Q4, Angion Biomedica earned $14.89 million, and total sales reached $25.94 million.